<DOC>
	<DOCNO>NCT01747096</DOCNO>
	<brief_summary>Evaluation diagnostic performance PET / CT 68Ga-DOTANOC Gastroenteropancreatic Neuroendocrine Tumors comparison technique use routine clinical practice ( octreoscan ® ; multiphase SPECT / CT , MRI endoscopy ) . Therapeutic impact safety PET / CT 68Ga-DOTANOC also assess . Expected result confirmation superiority 68Ga-PET DOTANOC versus scintigraphy octreoscan ® , potential impact therapeutic management patient .</brief_summary>
	<brief_title>TEP With 68-DOTANOC Gastroenteropancreatic Neuroendocrine Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Age 18 year effective contraception exclusion pregnancy dosage betaHCG woman childbearing age Fortuitous discovery suggestive tumor TEGEP well document conventional imaging ( multiphase CT ; MRI , US endoscopy ) associate associated clinical biological sign TEGEP tumor ( increase tumor marker ) OR Histologically proven GEPTE ( WHO classification 2010 ( 26 ) well differentiate initial staging OR Suspicion recurrence progression well differentiate TEGEP tumor conventional imaging laboratory test ( increase tumor marker ) OR Clinical biological syndrome strongly suggestive digestive endocrine disease without identification lesion conventional imaging Informed consent patient 's write Affiliation insurance Multiple endocrine neoplasia TE GEP tumor differentiate Pregnancy lactation Persons protect law Restlessness , inability lie still hold least 1 hour ; Claustrophobia Poor compliance predictable inability undergo medical test geographical , social psychological Treatment radiotherapy , chemotherapy antitumor treatment within 6 week previous morphological scintigraphic examination . In case treatment somatostatin analogue delay , scan perform 4 week last injection . However , short period may observe avoid initial assessment exam . malignancy except basal cell cancer cancer situ cervix Contraindication injection contrast agent necessary production multiphase scanner . Patients CT scan without injection contrast material participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Gastroenteropancreatic Neuroendocrine Tumors</keyword>
	<keyword>immuno PET ( iPET )</keyword>
	<keyword>Gallium ( 68-Ga )</keyword>
	<keyword>DOTANOC</keyword>
</DOC>